Upstart Class Action Adds Legal Overhang, But Fundamental Thesis Unchanged

What happened

A securities class action has been filed against Upstart, covering investors from May 14 to November 4, 2025, a period when the stock fell from ~$50 to ~$40. The lawsuit adds headline risk but does not alter the core investment thesis, which hinges on balance-sheet loan reduction and third-party funding absorption. Upstart's FY2025 results showed strong origination growth but also a warehouse covenant waiver in January 2026, signaling funding fragility. The company's bank charter application provides a potential long-term funding solution, but near-term earnings impact is limited until 2027. At $34.40, the stock remains a WAIT given elevated net debt/EBITDA of 15x and the need for observable proof that balance-sheet loans continue to shrink.

Implication

Investors should monitor for any additional covenant waivers or rise in on-balance-sheet loan share above 13%, which would confirm the bear case. Conversely, two quarters of declining balance-sheet loans and no further waivers would support the base case of $38. The class action may weigh on sentiment but does not change the fundamental value drivers.

Thesis delta

No shift from WAIT. The class action is a legal distraction that adds noise but does not alter the fundamental thesis centered on balance-sheet risk, covenant compliance, and bank charter progress.